Database→Humanin

Tier 3-4Anti-agingNeuroprotectionMitochondrialPREMIUM

Humanin

Humanin (HN) -- Mitochondria-Derived Peptide, Founding Member of the MDP Family

Not FDA-approved for any indication. No Investigational New Drug (IND) applications on public record. No human clinical trials registered on ClinicalTrials.gov as of April 2026. Not classified as a drug, dietary supplement, or biologic by the FDA. Available from peptide synthesis companies as a research chemical only. Not on WADA 2026 Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Humanin is a 24-amino acid mitochondria-derived peptide (MDP) encoded within the 16S rRNA gene (MT-RNR2) of mitochondrial DNA, discovered in 2001 simultaneously by three independent research groups. It is the founding member of the MDP family, which also includes MOTS-c and the SHLP peptides. Humanin has documented cytoprotective and neuroprotective effects across dozens of preclinical studies using cell culture and animal models. Human data is limited to observational biomarker studies: circulating humanin declines with age, is elevated in children of centenarians, and is associated with preserved coronary endothelial function. No human intervention trial of any kind has been completed. No IND has been filed. All dosing in community use is extrapolated from animal models without clinical validation.

🔒

Full Profile: Premium Members Only

The complete Humanin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use